BiondVax rounds up $9.5M in IPO

BiondVax ($BVXV) raised $9.5 million in a Nasdaq IPO, pricing 1,910,000 shares at $5.01 each. The Israel-based company is working on a universal flu vaccine to protect against all strains of the virus, including seasonal strains and pandemics. CEO Ron Babecoff said the funds will allow BiondVax to "promote its clinical activities and speed it up while developing business-wise," Globes reported. More

Suggested Articles

Amid the COVID-19 pandemic, many teams of researchers are working on potential vaccines. We asked experts to assess progress—and point out challenges.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.